GSK’s H1N1 vaccine approved by WHO, will go to developing countries
GlaxoSmithKline said Tuesday that its H1N1 pandemic vaccine manufactured in Canada has been approved by the World Health Organization for distribution in developing countries.
Prequalification from WHO ensures that a vaccine has met standards of quality and safety. This is the first prequalification for London-based GSK, which has its U.S. headquarters in Research Triangle Park where it employs more than 4,000 people.
